Better Health for All
60
Evotec's core business is drug discovery and development, with its entire portfolio dedicated to accelerating the discovery of new therapies. This includes an approved insomnia treatment,
1
an infectious diseases division researching antibacterial, antifungal, antituberculosis, and antiviral treatments,
2
and development of next-generation tuberculosis treatments aimed at reducing treatment duration and overcoming resistance.
3
The company's R&D and capital allocation are entirely focused on improving health outcomes, as evidenced by significant R&D spending in areas like cell and gene therapies,
4
and two US$2.5 million grants from the Bill & Melinda Gates Foundation for global health programs and tuberculosis treatment research.
5
,
6
The company also provides compound-management services to Medicines for Malaria Venture (MMV) supporting drug discovery for malaria and other neglected diseases.
7
Fair Money & Economic Opportunity
0
Evotec SE is a drug discovery and development company, not a financial institution that offers lending, deposit, or other financial services to consumers. Therefore, several KPIs related to consumer financial products and services are not applicable to its core business model. The company does not offer consumer credit products, nor does it generate revenue from high-cost financial products or penalty fees. It is not regulated as a lender and does not provide debt products to consumers. Evotec SE also does not operate financial service access points or offer financial products requiring disclosure or explanation. While the company reinvests profits into its growth strategy and environmental projects, there is no evidence of reinvestment specifically in community finance or profit-sharing with underserved communities.
1
Fair Pay & Worker Respect
0
The company's voluntary employee turnover rate was 12% in 2023.
1
Employee engagement, based on an overall employee rating, stands at 3.1 out of 5 stars.
2
Fair Trade & Ethical Sourcing
0
The provided articles, including the 2023 and 2024 Sustainability Reports and the 2024 Policy Statement on Human Rights, do not contain specific quantitative data for any of the Fair Trade & Ethical Sourcing KPIs. The reports explicitly state that key metrics related to fair trade, ethical sourcing, audit frequency, forced labor, traceability, remediation speed, materials risk index, and supplier diversity spend are either not quantified or absent.
1
While a Supplier Code of Conduct and a grievance procedure are mentioned, no percentage of supplier contracts with enforceable ethical clauses or data on remediation speed is provided. Similarly, the identification of child labor and forced labor as key risks does not equate to reporting substantiated incidents.
2
Honest & Fair Business
20
Evotec has a comprehensive global whistleblowing platform, EVOwhistle, available 24/7, which is a secure website
1
. It ensures confidentiality, provides notice of receipt within 7 days
2
, and communicates investigation outcomes within 3 months (90 days)
3
. In 2024, 22 reports were received and are under review
4
. The company had one financial restatement in the past five years, for IAS 19 in 2020
5
. Its consolidated financial statements and combined management report are 100% covered by an independent external audit by BDO AG Wirtschaftsprüfungsgesellschaft
6
, which has issued an unqualified opinion since fiscal year 2021
7
. All Supervisory Board members are stated to be independent
8
. Evotec has an Anti-Bribery and Corruption Compliance Policy that explicitly prohibits bribery, corruption, extortion, embezzlement, and facilitation payments, including specific rules on gifts, entertainment, insider trading, and transactions with healthcare providers
9
. The company conducts risk assessments and provides mandatory compliance training for all employees
10
.
Kind to Animals
0
Evotec extensively uses alternative methods, including in vitro pharmacological experiments, imaging, non-invasive methods, in silico tools, AI/ML, and organoids.
1
The company is working on over 25 iPSC-based research projects to sharply reduce animal experiments
2
, and non-animal models for drug-induced liver injury (DILI) show 86% predictive accuracy compared to 50% for animal models.
3
All research sites have applied for and been accredited by AAALAC International
4
, with re-accreditation occurring every three years.
5
Evotec has a Global Animal Welfare Policy, updated in 2019
6
and reviewed annually
7
, demonstrating a 30+ year commitment to the 3Rs principle (Replacement, Reduction, Refinement).
8
All animal experiments require regulatory approval
9
, justification for animal use, and minimization of animal numbers
10
, overseen by internal committees and animal welfare officers.
11
Evotec's subsidiary, Cyprotex, has a 5-year contract worth up to $13 million with the US EPA for a project utilizing in vitro methods to reduce animal testing.
12
Evotec also encourages collaboration with industry, academia, and federal agencies to accelerate the adoption of New Approach Methodologies (NAMs).
13
The company implements recommendations from laboratory animal science associations and the German Veterinary Association for Animal Welfare
14
, and aligns with the FDA Modernization Act 2.0.
15
National authorities consult expert commissions, including animal rights associations, when evaluating animal experiment applications.
16
Laboratory animal suppliers are certified breeders and are regularly audited.
17
No War, No Weapons
-40
Evotec SE, through its subsidiary Just-Evotec Biologics, has secured multiple contracts with the U.S. Department of Defense (DOD) for the development and manufacturing of medical countermeasures. These include a $74 million contract for monoclonal antibody prototypes against orthopoxviruses
1
, a $50 million contract for antibodies targeting bubonic plague
2
, a $28.6 million contract for COVID-19 monoclonal antibodies
3
, and a contract worth up to $39 million for manufacturing optimization
4
. The total value of these contracts is approximately $191.6 million. With a reported group revenue of €781.4 million in 2023
5
, these defense-related contracts represent approximately 22.7% of the company's revenue. The equipment developed is described as medical countermeasures, which are defensive in nature.
Planet-Friendly Business
-30
Evotec's total Scope 1, 2, and 3 greenhouse gas emissions in 2023 were 299,948 tCO2e
1
, with Scope 1 & 2 emissions reducing by 29% in 2023
2
and Scope 3 emissions decreasing by 34% between 2023 and 2024.
3
The company's near-term and long-term science-based targets, including a net-zero target by 2045, have been validated by SBTi as aligned with a 1.5°C pathway.
4
In 2024, 29% of all energy sources were from renewables
5
, with a target to reach 100% renewable electricity by 2026.
6
Water consumption intensity was 533.1 m3 per million euro of revenue generated.
7
In 2023, 59% of all waste generated was recovered.
8
69% of capital expenditure in 2023 was eligible under the EU Taxonomy.
9
The proportion of suppliers with science-based targets grew to 22% in 2024.
10
The company has a net-zero target year of 2045.
11
10% of water is consumed in water risk areas.
12
Evotec offers career transition assistance, reskilling opportunities, and internal mobility options for employees.
13
The company has not conducted a comprehensive risk assessment to evaluate potential locked-in GHG emissions from its key assets and products.
14
Respect for Cultures & Communities
20
Evotec SE provides formal grievance mechanisms for human rights and environmental violations, accessible via email, mail, and a digital whistleblowing system
1
. Feedback to whistleblowers is provided within three months.
2
Safe & Smart Tech
-20
Evotec experienced a cyber-attack on April 6, 2023
1
, involving malware and ransomware
2
, which caused communication disruption for 5,000 employees
3
and significantly impacted Q2 2023 operations, leading to revised financial guidance
4
. The company promptly shut down IT systems
5
, engaged a cybersecurity forensics team
6
, and informed relevant authorities
7
, with scientific data confirmed not affected
8
. Users have minimal control over their personal data, limited to managing communication preferences and unsubscribing from marketing emails
9
. Evotec uses at least 128-bit TLS encryption for email and web traffic
10
. The company retains data only as long as necessary for stated purposes
11
and states compliance with GDPR, CCPA, and SOX 404
12
, having informed relevant authorities about the cyber-attack
13
.
Zero Waste & Sustainable Products
-30
Evotec recovered 58% of its total waste generated in 2024.
1
The company has implemented numerous waste reduction initiatives, including a green chemistry working group focused on reducing hazardous substances, solvent replacement programs, and participation in the Freezer Challenge. Measurable results include the reuse of IT equipment, which reduced emissions by 26.5 tCO2e, and the recycling of over 20% (1000 kg) of nitrile gloves in the UK in 2023.
2
Evotec aims to achieve 0% landfill waste disposal at all its sites by 2025.
3
Hazardous waste management involves segregation, mitigation practices, and green chemistry initiatives, resulting in 56.8% of hazardous waste being diverted from disposal in 2024.
4
Evotec reported no significant waste disposal violations or fines in its 2021, 2022, 2023, and 2024 sustainability reports.
5
Furthermore, Evotec's Supplier Code of Conduct mandates suppliers to reuse or recycle materials, conserve natural resources, avoid hazardous materials, and identify product lifecycle environmental impacts.
6
Supplier assessments are conducted through the EcoVadis platform, and Evotec aims for 80% of its suppliers (by emissions) to have science-based targets by 2027.
7